| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers M > Headlines for Matritech Inc. > News item |
Matritech's NMP22 BladderChek Test detects cancers not found by cystoscopy, cytology, study says
By Lisa Kerner
Erie, Pa., April 6 - Matritech said its NMP22 BladderChek Test, a point-of-care urine test, detected occult bladder cancers that cystoscopy (visual exam using a scope) and cytology (lab test) failed to identify.
The company presented its findings at the 21st Annual Congress of the European Association of Urology in Paris.
The NMP22 BladderChek Test was reported to detect all of the cancers that occurred in the upper urinary tract of patients with risk factors or symptoms of bladder cancer, according to a company news release.
"Our challenge as urologists is to improve detection of bladder cancer," H. Barton Grossman of the University of Texas MD Anderson Cancer Center said in the release.
"Urinary tract cancer is the second most common urological malignancy after prostate cancer. In addition to detecting over three times as many tumors as the conventional urine test, cytology, the NMP22 test identified cancers in areas cystoscopy could not evaluate."
The inaccessibility of the upper urinary tract makes diagnosing bladder cancer a challenge. Adding the NMP22 test improved detection, the company said.
The NMP22 BladderChek Test detects elevated levels of the NMP22 protein marker in a single urine sample. Bladder cancer patients commonly have elevated NMP22 protein marker levels, even at early stages of the disease.
Matritech said the painless and noninvasive assay is the only in-office test approved by the Food and Drug Administration for the diagnosis of bladder cancer.
Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The company is located in Newton, Mass.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.